Real-World Effectiveness, Tolerability and Safety of Cyclosporine A 0.1% Cationic Emulsion in Severe Keratitis and Dry Eye Treatment

被引：0

作者：

Gerd Geerling

Samer Hamada

Stefan Trocmé

Sten Ræder

Xiangjun Chen

Claudia Fassari

Ines Lanzl

机构：

[1] University Hospital Düsseldorf,Department of Ophthalmology

[2] Queen Victoria Hospital,Aleris Specialistvård Sabbatsberg, Europakliniken Department of Ophthalmology

[3] Sabbatsbergs Hospital,undefined

[4] The Norwegian Dry Eye Clinic,undefined

[5] Santen SA,undefined

[6] Chiemsee Augentagesklinik,undefined

来源：

Ophthalmology and Therapy | 2022年 / 11卷

关键词：

Cyclosporine A 0.1% cationic emulsion; Dry eye disease; Real-world evidence; Severe keratitis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1101 / 1117

页数：16

共 114 条

[1] Craig JP(2017)TFOS DEWS II definition and classification report Ocul Surf 15 276-283
[2] Nichols KK(2017)TFOS DEWS II introduction Ocul Surf 15 269-275
[3] Akpek EK(2017)TFOS DEWS II pathophysiology report Ocul Surf 15 438-510
[4] Nelson JD(2017)TFOS DEWS II management and therapy report Ocul Surf 15 575-628
[5] Craig JP(1985)Tear water evaporation and eye surface diseases Ophthalmologica 190 147-149
[6] Akpek EK(2016)Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction Br J Ophthalmol 100 300-306
[7] Bron AJ(2018)Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting Acta Ophthalmol 96 111-119
[8] de Paiva CS(2017)TFOS DEWS II epidemiology report Ocul Surf 15 334-365
[9] Chauhan SK(2021)Dry eye disease flares: a rapid evidence assessment Ocul Surf 22 51-59
[10] Jones L(2021)Gathering non-traditional, 15 year, real-world patient insights into dry eye flares Invest Ophthalmol Vis Sci 62 1270-599